Parexel expands its regulatory reach with latest move

Global CRO Parexel International is looking to expand its regulatory consulting, launching a dedicated unit focused on the post-approval needs of drug and medical device developers.

After soaring 20% in 2013, Icon eyes a bigger share of the CRO market

Icon watched its revenue swell by 20% last year, and now the Irish CRO is expecting a healthy rate of new business wins to fuel growth in 2014.

Theorem takes a dive into analytics with latest deal

CRO Theorem Clinical Research has struck a deal with a healthcare analytics firm, giving it access to economics and outcomes research technology the company said can help drug developers make the right decisions throughout the R&D process.

Chiltern inks a deal with Karolinska Development

CRO Chiltern has hooked up with Karolinska Development, signing on to run clinical trials for the group's many projects.

Quintiles notches its first-ever $1B quarter as sales boom

Capping off a year in which it raised nearly $950 million in an up-sized IPO, Quintiles hauled in $1 billion in service revenue in the fourth quarter, a company first that sets the table for more growth in 2014.

After a 'pivotal' year, AMRI expects another leap in 2014

Last year, Albany, NY, contract developer AMRI watched its founding CEO retire and its business model evolve, shifting its priorities to deliver a jump in revenue, and now the company believes it's on track for bigger growth in 2014.

Parexel's rebranding makes a perceptible shift in its eClinical biz

Almost 10 years after closing a deal for the eClinical-focused Perceptive Informatics, CRO giant Parexel International is grafting its own name onto the subsidiary, part of a sweeping rebranding effort the company hopes will help nail down more partnerships.

Charles River's turnaround pays off with a strong 2013

Charles River Laboratories has pulled off a sweeping reorganization over the past few years, and the effort returned the preclinical CRO to revenue growth in 2013, setting the stage for another jump this year.

Report: CRO biz set for another boom

The global CRO market is likely to hit $23.6 billion this year, according to Industry Standard Research, an all-time high that will only be followed by faster growth.

AstraZeneca spares its WuXi-partnered drug in an R&D slash and burn

Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.

Wellcome bets $4M on CRO Selcia's university team-up

The U.K.'s Wellcome Trust is putting up about $4.1 million to fund a collaboration between CRO Selcia and Edinburgh University, under which the two will develop new treatments for sleeping sickness.

BioClinica plots an EU expansion in the midst of its latest merger

Last year, CRO BioClinica saw its most rapid growth in Europe, the company said, and now, as it prepares to join forces with CCBR-Synarc in its second merger in as many years, the clinical trial outfit plans to deepen its investment in the continent.

BioOutsource doubles its capacity in a bet on a biosimilar boom

As more and more massive-selling biologics lose their patent protection, a new class of biosimilars is poised to blow up around the world, and the U.K.'s BioOutsource is amping up its capabilities to prepare for the boom.

Covance's sales soar on a jump in late-stage testing

Global CRO Covance boosted its revenue by about 11% last quarter, capping off a banner year in which the company outstripped its financial targets.

Algorithme doubles down on complex trials with latest addition

Canadian CRO Algorithme Pharma has expanded its Montreal clinic to include a dedicated unit for complex trials, adding 41 beds to its flagship facility.

InVentiv looks to corner the market on mid-size biotechs

CRO conglomerate inVentiv Health has extended its deal with Swedish outfit NeuroVive Pharmaceutical, and the contract researcher says its ability to tailor its platform to developers of all sizes make it an ideal partner for drugmakers on the come-up.

Growing Novotech makes its way into Africa

Australian CRO Novotech is heading west with its global expansion effort, opening up shop in South Africa to broaden its access to diverse patient populations.

Ergomed cuts a risk-sharing deal on Ferrer's insomnia drug

The U.K.'s Ergomed takes a more hands-on approach to contract development than many CROs, and the company has inked another risk-sharing partnership, teaming up with Spain's Ferrer to progress an insomnia treatment.

Parexel rebounds from a shaky fall as sales jump 15%

After a hiccup in new business alarmed investors and overshadowed steady gains, Parexel righted the ship in its second fiscal quarter, boosting its new contracts and growing revenue by about 15%.

Indian CRO GVK buys its way into biologics with Aragen deal

India's GVK Biosciences has signed a deal to acquire Aragen Bioscience, a California-headquartered preclinical CRO, in an effort to tap into the booming demand for biologics development and expand its stateside market.